key: cord-0875410-8afn8k8o authors: Gibson, Anna M; Harris, Amy K; Spencer, Brian; Stroud, Angela; Huhnke, Gina; Bohleber, Amanda; Hinton, Ashley; Hurley, Jenny title: Rapid implementation of a new ambulatory infusion location for patients with COVID-19 to receive monoclonal antibody therapy date: 2021-02-18 journal: Am J Health Syst Pharm DOI: 10.1093/ajhp/zxab054 sha: 6c044d987195c56e57404b73d89dbe547a85b4ee doc_id: 875410 cord_uid: 8afn8k8o In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. A c c e p t e d M a n u s c r i p t Upon learning of the impending emergency use authorization (EUA) for the first monoclonal antibody therapy, our health system began working to operationalize the administration of a new ambulatory infusion unit. The ambulatory pharmacy manager was tasked with leading the effort and assembling the team. In the original brainstorm, discliplines included pharmacy, nursing, facilities, infection prevention and control, clinic administration, pre-cert, patient registration, and billing and finance. Potential locations were identified, and the team decided to use a temporary structure located outside the hospital near the emergency department entrance. The structure was readied for winter with insulation and an HVAC system, running water, locked refrigerator, and a medicine cabinet. The nursing department created a supply list, which was obtained by the materials management department within 24 hours. Infusion chairs, IV poles with pumps, and COWs (computers on wheels) were gathered from throughout the health system. The new unit at this location was deemed the "infusion annex" and was to be staffed by infusion nursing 7 days a week. The medication was to be compounded by the infusion pharmacy staff and delivered to the annex. This location would have capacity and staffing to treat 33 patients per day, utilizing 11 chairs from 0700 to 1730 daily. An emergency response plan was developed with portable oxygen, an emergency treatment cart, and infusion reaction treatments available. Because of the unit's proximity to the emergency department, patients could quickly be transported inside to be triaged by emergency personnel in the event of an urgent or emergent situation. Once the location had been secured, the team began working on the logistics of patient management. Members were added to the team, including staff from the emergency department, laboratory, call center, telehealth services, and electronic medical record (EMR) resources. A therapy plan was quickly built in the system, the infusion annex chair schedule was created, and billing was determined. The next step was to determine how we would ensure the patients met the qualifications outlined in the EUA. The team chose to obtain consent from the patients via a telehealth encounter, A c c e p t e d M a n u s c r i p t using providers experienced in doing on-demand, minor acute care telehealth visits. This part of the process increased efficiency by reducing travel for the patients and promoted safety by minimizing further exposure for staff and providers. The patients would be funneled through the previously established health system's Coronavirus disease 2019 (COVID-19) hotline, for screening by our clinical call center staff who were given scripting with a screening checklist. A note template was developed and constructed inside the EMR to assist the telehealth providers with the visit and patient education process. The pharmacy department educated the telehealth providers on the process to ensure they were comfortable with the needed assessment and consenting process. Educational materials were also sent to all primary care physicians within the health system to notify them of the process and to assist them in referring their patients with COVID-19 to be evaluated. The process was finalized as below: 1. Patients with COVID-19 were directed to call the COVID hotline, which was set up and answered by the call center staff. 2. The call center staff completed a screening process to determine if the patient qualified for treatment. 3. Patients were asked if they were interested in receiving treatment. 4 . Patients who agreed to receive treatment were scheduled for a telehealth visit with the telehealth provider team. 5. The telehealth providers reviewed the eligibility of the patient for the therapy, educated him/her regarding the treatment, and obtained verbal consent. 6. The patient was placed on the infusion annex schedule and directed where to go; a referral was placed in the system. 7. The patient arrived at the annex and was remotely registered into the EMR. 8. Nursing completed a brief assessment and ensured that the appropriate telehealth visit had been completed and the patient had received the required education. A c c e p t e d M a n u s c r i p t 9. The patient was given a written copy of the consent form to sign. 10. Pharmacy entered the medication orders, after reviewing the referral, then prepared the medication and delivered it to the annex. 11. Nursing administered the medication and monitored the patient for 1 hour. 12. The patient was discharged with instructions to call the COVID hotline with any issues. 13. Call center staff completed a post-infusion survey with the patient, on days 3 and 7, using the questions from the BLAZE-1 study. In addition, a process was developed to proactively reach out to patients with multiple risk factors. The screening process utilized a report from the EMR that gave a risk score to patients. The original plan was to reach out to patients with a risk score of 3, but it was quickly determined we could reduce that to 1. This tool predicts risk for readmission, but many of the variables used by the tool followed the criteria set forth by the EUA. Emergency authorization to add the medications to formulary was obtained from the pharmacy, therapeutics and diagnostics committee. Once the second monoclonal antibody was granted an EUA, we received authorization for a therapeutic interchange to use whichever product we received from our allocation. After the location was identified on November 11, 2020, it was operationalized in 2 days. The first infusion was completed the day that the medication was received, November 13, 2020. As of December 14, 2020, we have infused 435 patients. We are tracking and compiling the survey question results, hospital and emergency room (ER) admissions, and adverse drug reactions. Improvements to the process include:  Developing a triage for vital signs below defined cut-offs, in which the patient is not treated and is sent to the emergency department for evaluation.  Implementing a process for patients to be sent back to the annex if ER determines no need for admission. If the patient presents to the ER and is felt to be a candidate, then the COVID hotline is called to coordinate starting the defined process.  Educating the patients to call the nurse triage line, through our call center or their primary care physician's office, if they feel they are experiencing a side effect. Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab Lilly bamlanivimab antibody playbook Operation Warp Speed playbook for allocation and distribution of COVID-19 therapeutic medications SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. Epub ahead of print A c c e p t e d M a n u s c r i p t ___________________________